震裕科技(300953.SZ):擬在江蘇溧陽、寧德福安、四川宜賓等地投建新能源動力鋰電池精密結構件項目
格隆匯 4 月 25日丨震裕科技(300953.SZ)公佈,隨着國內外新能源汽車市場的快速發展,動力鋰電池市場需求擴張迅速,公司為進一步完善公司產能佈局,滿足客户產能配套需求,結合行業發展趨勢及公司戰略規劃,公司擬在江蘇溧陽、寧德福安、四川宜賓等地投資建設新能源動力鋰電池精密結構件項目。江蘇溧陽項目、寧德福安項目、四川宜賓項目的擬投資總額分別為人民幣16億元、人民幣4億元、人民幣5億元。
公司於2021年4月22日召開了第三屆董事會第十七次會議、第三屆監事會第九次會議,審議通過了《關於擬對外投資的議案》。本次投資事項尚需提交股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.